Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
---|---|---|---|---|---|---|
2012-10-30 | Vivalis (France) undisclosed large, international animal health firm | EB66® cell line | licensing |
Veterinary medicine | Licensing agreement | |
2012-10-30 | Wacker Biotech (Germany) XL-protein (Germany) | PASylated therapeutic proteins | collaboration |
Production agreement | ||
2012-10-29 | Astex Pharmaceuticals (USA) Cancer Research Technology (UK) Newcastle University (UK) | new cancer drugs | cancer | R&D |
Cancer - Oncology | R&D agreement |
2012-10-28 | ViiV Healthcare (UK-USA) Shionogi (Japan) | HIV integrase inhibitor portfolio, including dolutegravir | HIV-Aids | development commercialisation |
Infectious diseases | Development agreement |
2012-10-26 | Chugai Pharmaceutical (Japan) Kowa Company (Japan) Sanofi (France) | SGLT2 Inhibitor “CSG452” - tofoglifozin | type 2 diabetes | licensing |
Metabolic diseases | Licensing agreement |
2012-10-25 | Bayer (Germany) Qiagen (The Netherlands) | companion diagnostics paired with novel Bayer HealthCare drugs | cancer, various solid tumours | development |
Cancer - Oncology | Development agreement |
2012-10-25 | Red Glead Discovery (Sweden) SARomics Biostructures (Sweden) | lead compounds against epigenetic pathway targets | R&D |
R&D agreement | ||
2012-10-25 | Amgen (USA - CA) Kleiner Perkins Caufield & Byers (USA - CA) Atara Biotherapeutics (USA - CA) | licensing creation of a new company
|
Cancer - Oncology - Kidney diseases - Renal diseases | Licensing agreement | ||
2012-10-24 | Shire (UK) Fondazione Telethon (Italy) | 13 undisclosed rare disease indications related to lysosomal storage disorders and neurodegenerative diseases | R&D |
Rare diseases - Neurodegenerative diseases - Metabolic diseases | R&D agreement | |
2012-10-24 | Royal DSM (The Netherlands) Paranta Biosciences (Australia) | follistatin | respiratory diseases, inflammatory diseases | manufacturing |
Respiratory diseases - Inflammatory diseases | Production agreement |
2012-10-23 | Lonza (Switzerland) Oncomed Pharmaceuticals (USA) | anti-cancer stem cell therapeutics including Demcizumab,Anti-Notch 2/3 (OMP-59R5), Anti-Fzd7 (OMP-18R5), Anti-Notch1 (OMP-52M51), Anti-DLL4/VEGF Bi-Specific | development |
Cancer - Oncology | Production agreement | |
2012-10-23 | Theradiag (France) Sebia (France) | undisclosed diagnostic kit | undisclosed | development |
undisclosed | Development agreement |
2012-10-23 | Domain Therapeutics (France) Ono Pharmaceutical (Japan) | small molecules targeting G-Protein Coupled Receptors (GPCRs) selected by Ono | undisclosed | R&D |
undisclosed | R&D agreement |
2012-10-23 | Almirall (Spain) AB-Biotics (Spain) | pharmacogenetic tests including Neurofarmagen | acquisition |
Commercialisation agreement | ||
2012-10-23 | PolyTherics (UK) Biotecnol (USA) | multi-specific Tribody Drug Conjugates (TDCs) | cancer | development |
Cancer - Oncology | Development agreement |
2012-10-23 | Cellectis (France) NIH (USA) | generation of induced pluripotent stem (iPS) cell lines of research grade and differentiation of iPS cells toward specific tissue cell type for research use | services |
Services contract | ||
2012-10-23 | Fujifilm Diosynth Biotechnologies UK (UK) Piramal (india) | antibody drug conjugates (ADCs) | manufacturing |
Production agreement | ||
2012-10-23 | AstraZeneca (UK) Ironwood Pharmaceuticals (China) | linaclotide | irritable bowel syndrome with constipation (IBS-C) | development -commercialisation - promotion | Gastrointestinal diseases - Digestive diseases | Development agreement |
2012-10-22 | Genzyme (USA - MA), a Sanofi company (France) - Alnylam Pharmaceuticals (USA - MA) | RNAi therapeutics targeting transthyretin (TTR) | transthyretin-mediated amyloidosis (ATTR) | development - commercialisation | Rare diseases - Genetic diseases | Development agreement |
2012-10-18 | BioAlliance Pharma (France) Shafayab Gostar (Iran) | Loramyc® (miconazole Lauriad™) | oropharyngeal candidiasis in immunocompromised patients | distribution |
Infectious diseases | Distribution agreement |